CTLA4 and melanoma: Here we show that intra-tumoral administration of the TLR9 agonist ODN1826 [9] synergizes with CTLA-4 blockade to promote rejection of bi-laterally implanted B16-Ovalbumin (B16-Ova) melanoma.